Clinical Trials
8 trialsNCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT04045496 2025-12-29
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT04121286 2025-05-20
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
Phase 1 Completed
NCT03518554 2024-12-16
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT03565003 2024-09-25
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown